Overall Score

Base Case

AVXL remains a pre-revenue/zero-margin profile with TTM revenue, EBIT, EBITDA, and net profit margins all at 0, indicating no current operating profitability.

Liquidity is very strong with a current ratio of 18.24 and cash per share of 1.37, which supports near-term survival despite losses.

Valuation is still difficult to anchor on earnings or cash flow because TTM earnings yield and free cash flow yield are negative, reflecting ongoing losses and negative operating cash flow.

Bull Case

The balance sheet provides optionality, with working capital of 121.7M and net current asset value of 121.7M supporting continued development efforts.

Price-to-book of 2.45 is not extreme for a biotech-style optionality story if pipeline progress eventually improves fundamentals.

Income quality is 0.85, suggesting reported earnings are not heavily distorted, but this does not yet translate into positive operating performance.

Bear Case

The company is still burning cash, with operating cash flow per share of -0.37 and free cash flow per share of -0.37, keeping financing risk elevated.

Profitability remains deeply negative, with ROA of -26.5%, ROE of -31.4%, and ROIC of -31.7%, showing no evidence of operating leverage yet.

Solvency metrics remain weak despite high liquidity, as solvency ratio is negative and net debt to EBITDA is not meaningful given negative EBITDA.